Topical use of immunosupressor,Tacrolimus, in desquamative gingivitis patients: an open trial.

Phase 3

• Conditions: Desquamative gingivitis; Inflammatory and Immune System - Autoimmune diseases

• Registration Number: ACTRN12609000125224
• Lead Sponsor: niversity of Sao Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-02-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients exhibiting desquamative gingivitis with consent agreement.
There will be no exclusion by gender, age, or race, only if the patient is carrying a change of renal or hepatic

Exclusion Criteria

the patient with renal failure and / or liver

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effectiveness or lack of effectiveness followed through a chart that identifies presence and intensity of clinical signs (like ulcers, vesicles and erithema). Pain and discomfort will be checked by means of a Visual analogue scale (VAS).[VAS prior to drug delivery, 45-day and at the end of the period (90 day).<br>Clinical follow-up: starting point and every 15 days up to the end of 90-day period.]

Secondary Outcome Measures

Name	Time	Method
The results and effectiveness of the medication will be evaluated according to the type of disease by the professional researcher to compare the photos, using the VAS scale and the patient's complaint[45 and 90 days after the starting point.]